OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington’s disease mouse model
Sarah B. Thomson, Anouk Stam, Cynthia Brouwers, et al.
Brain (2022) Vol. 146, Iss. 6, pp. 2298-2315
Closed Access | Times Cited: 13
Sarah B. Thomson, Anouk Stam, Cynthia Brouwers, et al.
Brain (2022) Vol. 146, Iss. 6, pp. 2298-2315
Closed Access | Times Cited: 13
Showing 13 citing articles:
Delivery of Adeno-Associated Virus Vectors to the Central Nervous System for Correction of Single Gene Disorders
Rrita Daci, Terence R. Flotte
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1050-1050
Open Access | Times Cited: 15
Rrita Daci, Terence R. Flotte
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1050-1050
Open Access | Times Cited: 15
Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington disease models
Marina Sogorb-González, Christian Landles, Nicholas S. Caron, et al.
Brain (2024) Vol. 147, Iss. 12, pp. 4043-4055
Open Access | Times Cited: 4
Marina Sogorb-González, Christian Landles, Nicholas S. Caron, et al.
Brain (2024) Vol. 147, Iss. 12, pp. 4043-4055
Open Access | Times Cited: 4
CAG-targeted brain-permeable therapy tested in biallelic humanized polyQ mouse models
Magdalena Surdyka, Żaneta Kalinowska-Pośka, Anna Niewiadomska-Cimicka, et al.
Molecular Therapy — Nucleic Acids (2025) Vol. 36, Iss. 2, pp. 102496-102496
Open Access
Magdalena Surdyka, Żaneta Kalinowska-Pośka, Anna Niewiadomska-Cimicka, et al.
Molecular Therapy — Nucleic Acids (2025) Vol. 36, Iss. 2, pp. 102496-102496
Open Access
The contribution of preclinical magnetic resonance imaging and spectroscopy to Huntington’s disease
J. Pérot, Emmanuel Brouillet, Julien Flament
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 3
J. Pérot, Emmanuel Brouillet, Julien Flament
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 3
Current clinical trials of new therapeutic agents for Huntington's disease
Blair R. Leavitt
Elsevier eBooks (2024), pp. 571-589
Closed Access | Times Cited: 3
Blair R. Leavitt
Elsevier eBooks (2024), pp. 571-589
Closed Access | Times Cited: 3
Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks
Amirah E.-E. Aly, Nicholas S. Caron, Hailey Findlay Black, et al.
Journal of Controlled Release (2023) Vol. 360, pp. 913-927
Open Access | Times Cited: 6
Amirah E.-E. Aly, Nicholas S. Caron, Hailey Findlay Black, et al.
Journal of Controlled Release (2023) Vol. 360, pp. 913-927
Open Access | Times Cited: 6
Sequencing-guided design of genetically encoded small RNAs targeting CAG repeats for selective inhibition of mutant huntingtin
Mansi Parasrampuria, Adam A White, Ramadevi Chilamkurthy, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 2, pp. 102206-102206
Open Access | Times Cited: 2
Mansi Parasrampuria, Adam A White, Ramadevi Chilamkurthy, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 2, pp. 102206-102206
Open Access | Times Cited: 2
Systems biology study of Huntington's disease
Leonardo E. Dionisio, Peter Langfelder, Jeffrey S. Aaronson, et al.
Elsevier eBooks (2024), pp. 353-396
Closed Access | Times Cited: 1
Leonardo E. Dionisio, Peter Langfelder, Jeffrey S. Aaronson, et al.
Elsevier eBooks (2024), pp. 353-396
Closed Access | Times Cited: 1
Huntingtin lowering impairs the maturation and synchronized synaptic activity of human cortical neuronal networks derived from induced pluripotent stem cells
Mathilde Louçã, Donya El Akrouti, Aude Lemesle, et al.
Neurobiology of Disease (2024) Vol. 200, pp. 106630-106630
Open Access | Times Cited: 1
Mathilde Louçã, Donya El Akrouti, Aude Lemesle, et al.
Neurobiology of Disease (2024) Vol. 200, pp. 106630-106630
Open Access | Times Cited: 1
Arguments for and against the whole-genome sequencing of newborns.
Csaba Szalai
PubMed (2023) Vol. 15, Iss. 10, pp. 6255-6263
Closed Access | Times Cited: 1
Csaba Szalai
PubMed (2023) Vol. 15, Iss. 10, pp. 6255-6263
Closed Access | Times Cited: 1
Longitudinal study of neurochemical, volumetric and behavioral changes in Q140 & BACHD mouse models of Huntington’s disease
Lori Zacharoff, Ivan Tkáč, Alexander Shapiro, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Lori Zacharoff, Ivan Tkáč, Alexander Shapiro, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Suppression of CNS APOE4 Expression by miRNAs Delivered by the S2 AAVrh.10 Capsid-modified AAV Vector
Kalpita R. Karan, Sławomir Andrzejewski, Katie M. Stiles, et al.
Human Gene Therapy (2024) Vol. 35, Iss. 21-22, pp. 904-916
Closed Access
Kalpita R. Karan, Sławomir Andrzejewski, Katie M. Stiles, et al.
Human Gene Therapy (2024) Vol. 35, Iss. 21-22, pp. 904-916
Closed Access
Using gene or cell therapies to treat Huntington's disease
Caroline S. Binda, Mariah J. Lelos, Anne Rosser, et al.
Handbook of clinical neurology (2024), pp. 193-215
Closed Access
Caroline S. Binda, Mariah J. Lelos, Anne Rosser, et al.
Handbook of clinical neurology (2024), pp. 193-215
Closed Access
